GW says Canada backs cannabis drug for cancer pain
LONDON (Reuters) - Britain’s GW Pharmaceuticals Plc said on Tuesday its pioneering cannabis-based drug Sativex had qualified to be considered for approval by Canadian regulators as a treatment for cancer pain.
Information and News on Health and Beauty.
Read full story